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Abstract
Amyloid imaging plays an important role in the research and diagnosis of dementing disor-
ders. Substantial variation in quantitative methods to measure brain amyloid burden exists
in the field. The aim of this work is to investigate the impact of methodological variations to
the quantification of amyloid burden using data from the Dominantly Inherited Alzheimer’s
Network (DIAN), an autosomal dominant Alzheimer’s disease population. Cross-sectional
and longitudinal [11C]-Pittsburgh Compound B (PiB) PET imaging data from the DIAN study
were analyzed. Four candidate reference regions were investigated for estimation of brain
amyloid burden. A regional spread function based technique was also investigated for the
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correction of partial volume effects. Cerebellar cortex, brain-stem, and white matter regions
all had stable tracer retention during the course of disease. Partial volume correction consis-
tently improves sensitivity to group differences and longitudinal changes over time. White
matter referencing improved statistical power in the detecting longitudinal changes in rela-
tive tracer retention; however, the reason for this improvement is unclear and requires fur-
ther investigation. Full dynamic acquisition and kinetic modeling improved statistical power
although it may add cost and time. Several technical variations to amyloid burden quantifi-
cation were examined in this study. Partial volume correction emerged as the strategy that
most consistently improved statistical power for the detection of both longitudinal changes
and across-group differences. For the autosomal dominant Alzheimer’s disease population
with PiB imaging, utilizing brainstem as a reference region with partial volume correction
may be optimal for current interventional trials. Further investigation of technical issues in
quantitative amyloid imaging in different study populations using different amyloid imaging
tracers is warranted.
Introduction
Alzheimer’s disease (AD) is the most common form of dementia [1] with its prevalence
expected to dramatically increase in the next 50 years [2]. AD pathology begins to accumulate at
least 10 to 20 years before clinical symptoms appear [1,3,4], and there is a growing consensus
that effective treatment of AD will require early intervention [5,6]. The amyloid cascade is the
primary target of the largest ongoing clinical trials [7], including DIAN-TU (DIAN Trial Unit)
[8], A4 trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) [9], and API
(Alzheimer’s Prevention Initiative) [10] in preclinical population. Well validated biomarkers of
amyloid accumulation are needed for these treatment development efforts and trial design [5,6].
The most commonly used quantification technique for amyloid Positron Emission Tomog-
raphy (PET) imaging involves comparing regional uptake to cerebellar cortex [11,12]. How-
ever, the observation of amyloid deposition in the cerebellar cortex of familial AD cases [13,14]
had led to the identification and validation of pons as an alternative reference region [15]. A
large white matter region of interest (ROI) has been proposed as an reference region to provide
improved discrimination between clinically defined groups [16]; and a smaller “core” white
matter reference region was reported to improve the detection of changes in tracer retention in
longitudinal studies within the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [18F]-
florbetapir data [17].
Correction of partial volume effects represents another area of active investigation [18].
PET imaging based measurement is subjected to partial volume effects, because of the low spa-
tial resolution [19]. Although partial volume effects are well-recognized, correction techniques
remain controversial. One study comparing two-component (brain and non-brain) vs. three-
component (gray matter, white matter, non-brain) reported relative advantages and disadvan-
tages of both methods [20]. Thomas et al. [21] reported improved quantitative accuracy using
a region-based voxel-wise partial volume correction (PVC) method. More recently, Brendel
et al. [16] and our group [18] found PVC improved the power to detect longitudinal amyloid
burden change.
A third methodological choice concerns the quantitative model used to determine amyloid
burden. The most commonly used approach is the target-to-reference region standard-uptake-
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value-ratio (SUVR) [4,16,17]. SUVR evaluation is simple and only requires a short acquisition,
which translates to low cost. However, SUVR measurements are sensitive to the choice of tem-
poral window used for evaluation, in part, owing to individual variability in cerebral perfusion
[16,22]. Alternatively, kinetic modeling techniques [23,24] can be used to calculate distribution
volume ratio (DVR) or binding potential (BPND) as a quantitative measure of amyloid burden
[11,22]. These techniques require longer dynamic PET acquisitions initiated in synchrony with
tracer administration and are less attractive because of increased participant burden, study cost
and complexity of quantification.
It should be pointed out that currently a “gold standard” technique that objectively mea-
sures brain amyloid burden is not available for validation of in vivo amyloid PET measure-
ments. Some other criteria are often used to judge the performance of amyloid quantification
techniques. These criteria include low inter-subject variability in reference regions [15,22],
strong group differences between control subjects and AD patients [15,16,22], and, in longitu-
dinal studies, strong longitudinal changes [16,17,25]. Here, we investigate the impact of 1) ref-
erence region selection; 2) correction for partial volume effects; and 3) choice of quantification
technique using cross-sectional and longitudinal [11C]-Pittsburgh Compound B (PiB) imaging
data from the DIAN study. Regional SUV and volume of distribution (VT) were used to deter-
mine the stability of reference regions tracer uptake by comparing mutation carriers against
non-carriers. The power of detecting longitudinal changes was also examined to compare dif-
ferent amyloid quantification techniques.
Materials and Methods
Participants
The participants included in this study were recruited as part of the international Dominantly
Inherited Alzheimer Network (DIAN) [26]. The DIAN includes individuals from families with
known autosomal dominant mutation in amyloid precursor protein [27], presenilin 1 [28], or
presenilin 2 [29] genes leading to early onset AD. The current study was based on the eighth
semiannual data cutoff with a total of 341 participants who had at least one PiB scan; among
them 203 were mutation carriers (APP = 27, PSEN1 = 161, PSEN2 = 15); within these 203 par-
ticipants, 59 had usable PiB scans for at least two visits on the same scanners and formed the
longitudinal mutation carrier cohort (LC). For participants with more than two PiB scans, the
first two usable visits with an interval as close to 2 years as possible (range 0.8–3.3 yrs) was
included in this study. The same scanner rule was enforced to minimize the impact of scanner
difference. Within the LC cohort, a subset of 23 participants (LC_Dyn) had full dynamic scans
at both time points. A longitudinal cohort for non-carriers (LNC) was also selected using the
same criteria and had a total of 36 participants. A cross-sectional cohort (CC) was selected
from theWashington University in St. Louis (WU) site DIAN cohort, including 69 participants
(38 mutation carriers) with valid baseline PiB scans on the same PET scanner. Single scanner
data minimizes differences in scanner calibration protocols. In addition, 42 participants (21
mutation carriers) from the WU site who had time-of-flight (TOF) MR angiography (MRA)
scans and 70-min dynamic PiB PET scans were included for absolute quantification (AQ) of
PiB binding using an image-derived arterial input function (IDAIF) technique [30]. Demo-
graphic details of these cohorts are provided in Table 1.
All assessment and imaging procedures were approved by the WUHuman Research Protec-
tion Office. Written informed consent was obtained from all individuals or their care-givers.
Local institutional review boards (Columbia University Institutional Review Board; University
of Pittsburgh Human Research Protection Office; UCLA Institutional Review Boards; Indiana
University Institutional Review Boards; Partners Human Research Committee; Butler
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Hospital's Institutional Review Board for Human Subjects Research; The University of New
South Wales Human Research Ethics Committee; University of Melbourne Office for Research
Ethics and Integrity; Edith Cowan University Human Research Ethics Committee; and Univer-
sity College London Research Ethics Committee) also approved the collection of scans for
archiving and future study at each non-WU study site.
Clinical Assessment
The clinical assessment protocol has been previously described [3,4]. In brief, dementia status
was assessed using the clinical dementia rating (CDR) [31]. Estimated year to onset (EYO) was
calculated as the difference between the participant’s age at evaluation and the age at which
parental cognitive decline began [3]. The ADADmutation status was determined using poly-
merase chain reaction based amplification of the appropriate exon followed by Sanger sequenc-
ing [3]. Each participant’s apolipoprotein E (APOE) genotype was determined using previously
described methods [32]. Clinical evaluators were blind to participant mutation status.
Image Acquisition
Imaging protocol has been described in detail previously [4]. PiB PET acquisition consisted of
either a 70-min dynamic scan starting at injection or a 30-min scan with 40 minutes uptake
time. Accelerated 3D sagittal T1-weighted images of the head were acquired in each partici-
pant. TOF-MRA data was acquired with during the same imaging session as the T1-weighted
structural scan for the AQ cohort.
Image Analysis
Our image analysis technique has been previously described in detail [12]. In summary, Free-
Surfer v5.1 (Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, USA,
https://surfer.nmr.mgh.harvard.edu/fswiki) was used to automatically segment the brain using
T1-weighted MR acquired in corresponding visit as the PET scan. A PET Unified Pipeline
(PUP) (https://github.com/ysu001/PUP) was used for automated PET data analysis [12,18]. In
Table 1. Demographics Summary.
Cohort LC LC_Dyn CC_Carrier CC_Noncarrier AQ_Carrier AQ_Noncarrier LNC
N 59 23 38 31 21 20 36
Age (SD) years 42.6 (8.7) 44.8 (10.8) 38.4 (10.5) 39.3 (9.5) 37.4 (11.2) 39.9 (9.1) 41.3 (9.6)
EYO (SD) years -2.1 (8.6) -1.1 (11.3) -8.8 (9.4) -5.7 (10.9) -10.0 (10.3) -5.5 (9.6) -4.5 (10.2)
Education (SD) years 14.0 (2.8) 15.0 (3.2) 15.5 (3.1) 15.5 (2.4) 15.2 (2.6) 15.5 (2.5) 14.9 (2.2)
Interval (SD) years 1.7 (0.8) 1.9 (0.8) - - - - 2.4 (0.9)
Male (%) 30 (50.8) 17 (73.9) 27 (71.1) 15 (48.4) 16 (76.1) 9 (45.0) 14 (38.9)
APOE4+ (%) 23 (39.0) 11 (47.8) 14 (36.8) 10 (32.3) 11 (52.3) 5 (25.0) 11 (30.6)
CDR>0 (%) 28 (47.5) 10 (43.5) 11 (28.9)* 0 (0) 4 (19.0) 0 (0) 0 (0)
MMSE (SD) 26.2 (5.2) 28.2 (2.5)† 28.2 (3.4)* 29.6 (0.6) 28.1 (3.1) 29.4 (0.7) 29.1 (1.1)
LC = longitudinal cohort; CC_Carrier = cross-sectional cohort mutation carrier; CC_Noncarrier = cross-sectional cohort non-carrier; AQ_Carrier = absolute
quantiﬁcation cohort mutation carrier; AQ_Noncarrier = absolute quantiﬁcation cohort non-carrier; LNC = longitudinal non-carrier cochort; baseline values
were reported for LC and LNC; EYO = estimated years to onset; SD = standard deviation; APOE4+ = apolipoprotein E ε4 gene carrier; CDR = clinical
dementia rating; MMSE = Mini Mental State Examination
*signiﬁcantly different from corresponding non-carrier group
†signiﬁcantly different from the LC group
doi:10.1371/journal.pone.0152082.t001
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the default SUVR analysis, regional SUVR was calculated using cerebellar cortex as the refer-
ence region and PET data acquired between 40 and 70 minutes post-injection. When a full
70-min dynamic scan was available, regional time-activity curve for each ROI was extracted
followed by regional binding potential (BPND) (DVR-1) estimation using Logan graphical anal-
ysis with the cerebellar cortex (CER) serving as the reference [23]. Mean cortical binding
potentials (MCBP) [11] and mean cortical SUVR (MCSUVR) were calculated based on a
selected set of cortical FreeSurfer regions [12]. PVC was also performed using a regional spread
function (RSF) technique implemented in PUP [18], which is also known as the geometric
transfer matrix (GTM) technique [33]. Regional SUVR and BPND were estimated with and
without PVC.
Alternative Reference Region
Recent papers [15–17] have proposed three alternative SUVR reference regions. We imple-
mented these alternative reference regions based on FreeSurfer segmentation (Fig 1). The brain
stem (BS) region was used to approximate the pontine reference, as proposed by Edison et al.
[15]. A core white matter (CW) reference region, as proposed by Chen et al. [17], was approxi-
mated by combining corpus callosum and the ROI labelled as “UnsegmentedWhiteMatter” by
FreeSurfer. A total white matter (TW) reference region was also constructed using all the cere-
bral white matter [16].
Cross-sectional SUV Analysis
For the cross-sectional cohort, regional SUV were estimated by normalizing regional activity
concentration with injection dose and body weight. SUV values were calculated for the four
candidate reference regions (CER, BS, CW, and TW) and the mean cortical (MC) regions
using the same time window as the SUVR analysis.
Absolute Quantification
An IDAIF was obtained using a recently developed technique by combined analysis of
TOF-MRA, T1-weighted MR, and dynamic PET imaging data [30,34]. Logan graphical analy-
sis [35] was then applied to obtain regional VT, which is a measurement of absolute tracer
binding. The quantification was performed on the same set of regions as the SUV analysis, and
results were presented with and without PVC.
Longitudinal Analysis
Longitudinal change in amyloid burden was assessed as the absolute change (delta), percent
change (delta%) and annual rate of change (rate) in MCSUVR using all four candidate refer-
ence regions with and without RSF PVC. Follow-up MCSUVRs were compared with their cor-
responding baseline measurements using paired t-test. Cohen’s d effect size measure was
calculated based on the mean and standard deviation of the annual rate of change in MCSUVR.
Percent change in MCSUVR was also compared between quantification methods using paired
t-test. In addition, we also estimated the number of participants per arm needed to detect a
25% and 50% reduction in amyloid accumulation rate due to treatment with 80% power and a
two-tailed type-I error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial.
The 25% reduction was selected to match a similar study [17]. The 50% reduction was included
to approximate hypothesized treatment effects in anti-amyloid treatment trials. The sample
size calculation was performed using MATLAB (R2015b) (The Mathworks Inc, Natick, MA)
function: sampsizepwr, in the statistics and machine learning toolbox v10.1. The calculation
Quantitative Amyloid PET Imaging
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was performed based on the observed annual rate of change in MCSUVR and its standard devi-
ation. LNC cohort data were also analyzed as a test-retest study, since amyloid burden and its
change are not expected in this cohort of young participants. A test-retest variability measure
was defined as:TRT% = (|M1-M2|/M1)×100%, whereM1 was the amyloid burden measurement
at baseline andM2 was the follow-up measurement. The mean and standard deviation of TRT
% was evaluated for the LNC cohort and compared among different quantification methods.
Results
Cross-sectional SUV Analysis
Significant MCSUV differences were observed between mutation carriers and non-carriers
with and without PVC (Table 2). SUVs for the TW region were significantly different between
Fig 1. Example reference regions. (BS: Brain-Stem; CER: Cerebellar Cortex; CW: Core White Matter; TW: Total White Matter).
doi:10.1371/journal.pone.0152082.g001
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mutation carriers and non-carriers, however, PVC removes this difference. Regional SUVs
were not significantly different for any of the other three reference regions regardless of PVC.
Absolute Quantification
VT was significantly different for MC regions between the mutation carriers and non-carriers,
and PVC led to smaller p values (Table 3). No group differences in regional VT were observed
for any of the reference regions.
Longitudinal Analysis
For the LC cohort, using either cerebellar cortex or brain stem as the reference region, longitudi-
nal MCSUVR change was not significant without partial volume, while PVC revealed the change
(Table 4). Using core white matter and total white matter reference regions revealed significant
longitudinal change in MCSUVR with or without PVC (Table 4). The MCSUVR change from
baseline to follow-up had the smallest p values with (p = 0.0000075) and without (p = 0.000017)
PVC when core white matter was used as the reference. PVC and using white matter as reference
region also led to larger effect size (Table 4). PVC based analysis generated significantly
(p<0.0005) larger longitudinal percent change in MCSUVR regardless of the reference regions
used (Table 4). PVC and adoption of white matter as reference led to a considerably smaller esti-
mated sample size needed to achieve an 80% power and two-sided type-I error of p = 0.05 to
detect a reduced rate of amyloid accumulation in hypothetical anti-amyloid therapy trials.
For the LNC cohort, no change in MCSUVR was observed, as expected, between baseline
and follow-up regardless of the quantification methods used. It is observed that cerebellar cor-
tex referencing led to the smallest test-retest variability (Table 5), while the other reference
regions did not differ significantly.
Table 2. Regional SUV for the cross-sectional cohort.
MC CER BS CW TW MCRSF CERRSF BSRSF CWRSF TWRSF
Noncarrier 0.64±0.11 0.60±0.10 0.96±0.20 0.99±0.21 0.87±0.18 0.56±0.10 0.56±0.09 1.06±0.23 1.07±0.24 1.04±0.24
Carrier 0.97±0.39 0.62±0.12 0.97±0.20 1.00±0.20 1.00±0.27 1.26±0.73 0.58±0.12 1.07±0.24 1.02±0.20 1.01±0.21
p 9.10E-06 3.55E-01 8.53E-01 9.29E-01 1.43E-02 8.76E-07 3.37E-01 8.92E-01 3.27E-01 6.60E-01
MC = mean cortical regions; CER = cerebellar cortex; BS = brainstem; CW = core white matter; TW = total white matter; MCRSF = mean cortical regions
with RSF partial volume correction; CERRSF = cerebellar cortex with RSF partial volume correction; BSRSF = brainstem with RSF partial volume
correction; CWRSF = core white matter with RSF partial volume correction; TWRSF = total white matter with RSF partial volume correction; p is the
strength of the group difference, i.e. noncarrier vs. carrier, for each region of interest based on student t-test.
doi:10.1371/journal.pone.0152082.t002
Table 3. Regional volume of distribution (VT) estimated using image-derived arterial input function.
MC CER BS CW TW MCRSF CERRSF BSRSF CWRSF TWRSF
Noncarrier 2.79±1.00 2.75±0.98 3.66±1.27 3.71±1.49 3.35±1.26 3.16±1.14 2.83±1.02 4.20±1.45 4.13±1.81 3.90±1.56
Carrier 3.70±1.07 2.71±0.62 3.55±0.80 3.68±0.86 3.77±0.87 5.20±2.06 2.80±0.64 4.06±0.93 3.79±1.01 3.72±0.86
p 7.78E-03 8.83E-01 7.28E-01 9.22E-01 2.27E-01 4.17E-04 9.07E-01 7.14E-01 4.69E-01 6.54E-01
MC = mean cortical regions; CER = cerebellar cortex; BS = brainstem; CW = core white matter; TW = total white matter; MCRSF = mean cortical regions
with RSF partial volume correction; CERRSF = cerebellar cortex with RSF partial volume correction; BSRSF = brainstem with RSF partial volume
correction; CWRSF = core white matter with RSF partial volume correction; TWRSF = total white matter with RSF partial volume correction; p is the
strength of the group difference, i.e. noncarrier vs. carrier, for each region of interest based on student t-test.
doi:10.1371/journal.pone.0152082.t003
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Impact of Dynamic Acquisition
The estimated sample sizes for anti-amyloid therapy trials were smaller based on LC_Dyn data
compared to the LC and the observed longitudinal MCSUVR change had smaller p values and
larger effect size (Table 6 vs. Table 4). PVC had less of an impact on BPND compared to SUVR
analyses.
Discussion
Reference Region
Both SUV analysis and IDAIF based absolute quantification showed all four reference regions
were not different between mutation carriers and non-carriers. White matter referencing,
Table 4. Longitudinal SUVR analysis for mean cortical regions in mutation carriers.
MC_CER MC_BS MC_CW MC_TW MCRSF_CER MCRSF_BS MCRSF_CW MCRSF_TW
Baseline 1.73±0.58 1.15±0.35 1.08±0.31 0.99±0.14 2.54±1.28 1.43±0.63 1.53±0.73 1.43±0.56
follow-up 1.76±0.60 1.17±0.35 1.12±0.32 1.00±0.14 2.65±1.36 1.48±0.64 1.64±0.80 1.49±0.57
delta 0.03±0.11 0.01±0.07 0.04±0.07 0.01±0.03 0.11±0.26 0.05±0.10 0.11±0.17 0.06±0.11
delta% 1.63±7.04 1.51±6.30† 3.34±5.88 1.29±3.54 4.19±11.07*‡ 4.08±9.86*‡ 7.03±11.27* 5.05±9.82*
p (follow-up vs. Baseline) 7.22E-02 1.39E-01 1.70E-05 8.12E-03 8.78E-04 6.25E-04 7.46E-06 1.14E-04
Rate 0.01±0.08 0.00±0.04 0.02±0.04 0.01±0.02 0.07±0.18 0.02±0.06 0.07±0.13 0.04±0.07
Effect Size 0.15 0.07 0.55 0.38 0.38 0.38 0.51 0.50
sample size (25% reduction in Rate) 5714 24165 411 885 858 852 480 502
sample size (50% reduction in Rate) 1430 6043 105 223 216 215 122 127
MC_CER = mean cortical region SUVR using cerebellar cortex as reference; MC_BS = mean cortical region SUVR using brainstem as reference;
MC_CW = mean cortical region SUVR using core white matter as reference; MC_TW = mean cortical region SUVR using total white matter as reference;
MCRSF_CER = mean cortical region SUVR using cerebellar cortex as reference with RSF partial volume correction; MCRSF_BS = mean cortical region
SUVR using brainstem as reference with RSF partial volume correction; MCRSF_CW = mean cortical region SUVR using core white matter as reference
with RSF partial volume correction; MCRSF_TW = mean cortical region SUVR using total white matter as reference with RSF partial volume correction;
delta = change in SUVR from baseline to follow-up; delta% = percent change in SUVR from baseline to follow-up; p is the strength of the difference
between follow-up and baseline SUVRs based on a paired t-test; Rate = the annual rate of SUVR change; sample size is the estimated number of
participants per arm needed to detect a 25% or a 50% reduction in amyloid accumulation rate due to treatment with 80% power and a two-tailed type-I
error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial.
*percent change in MCSUVR signiﬁcantly greater with PVC than without (p<0.0005)
†percent change in MCSUVR signiﬁcantly smaller than CW referencing (p<0.01)
‡percent change in MCSUVR with PVC signiﬁcantly smaller than CW referencing (p<0.05)
doi:10.1371/journal.pone.0152082.t004
Table 5. Reproducibility of PiBmeasurements based on the longitudinal non-carriers cohort (LNC).
MC_CER MC_BS MC_CW MC_TW MCRSF_CER MCRSF_BS MCRSF_CW MCRSF_TW
TRT% (Mean±SD) 3.0±2.7 4.0±3.8 4.5±4.0 3.0±2.4 5.0±3.7 7.1±7.3 9.2±8.3 8.5±7.5
MC_CER = mean cortical region SUVR using cerebellar cortex as reference; MC_BS = mean cortical region SUVR using brainstem as reference;
MC_CW = mean cortical region SUVR using core white matter as reference; MC_TW = mean cortical region SUVR using total white matter as reference;
MCRSF_CER = mean cortical region SUVR using cerebellar cortex as reference with RSF partial volume correction; MCRSF_BS = mean cortical region
SUVR using brainstem as reference with RSF partial volume correction; MCRSF_CW = mean cortical region SUVR using core white matter as reference
with RSF partial volume correction; MCRSF_TW = mean cortical region SUVR using total white matter as reference with RSF partial volume correction;
TRT% = (|M1-M2|/M1)×100% is the test-retest reproducibility of SUVR measurement.
doi:10.1371/journal.pone.0152082.t005
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especially using core white matter ROI, improved the sensitivity for detecting longitudinal
changes in MCSUVR, however, the cause of this improvement is unclear and requires further
investigation. White matter PiB uptake was not more stable in either the non-carrier control
population or the mutation carrier participants. In fact, the coefficient of variation was greater
for white matter than for cerebellar cortex and brain stem. In the LNC cohort, larger test-retest
variability was observed when core white matter was used as reference region in comparison to
cerebellar cortex referencing. On the other hand, a (non-significant) trend was observed
towards lower white matter uptake (for both core and total white matter regions) for mutation
carriers than noncarriers in the IDAIF analysis and partial volume corrected SUV, suggesting
potential changes in white matter region properties in the mutation carriers that may alter
white matter tracer uptake. We suspect such changes in the white matter region over time may,
in part, be the cause of the improved power in detecting longitudinal MCSUVR change using
white matter referencing. In addition, the observed longitudinal change in MCSUVR agreed
well (Pearson r = 0.66, p = 1.03E-8) when cerebellar cortex and brain stem were used as the ref-
erence region. However, the longitudinal MCSUVR changes measured using white matter as
reference region did not agree (Pearson r = 0.25, p = 0.052) with the results obtained using cer-
ebellar cortex referencing. These differences suggest that using white matter as the reference
region potentially leads to less consistent results.
Partial Volume Correction
We show that PVC enhances sensitivity for the detection of longitudinal changes in PiB bind-
ing in the DIAN cohort, in accordance with our previous report in a sporadic AD cohort [18].
Table 6. Mean cortical measurement for longitudinal cohort participants with full dynamic PiB.
MC_CER MC_BS MC_CW MC_TW MCRSF_CER MCRSF_BS MCRSF_CW MCRSF_TW MCBP MCBPRSF
Baseline 1.83
±0.59
1.18
±0.35
1.12
±0.31
1.02
±0.16
2.80±1.33 1.50±0.64 1.60±0.71 1.54±0.62 0.62
±0.45
1.33±0.93
follow-up 1.89
±0.58
1.22
±0.35
1.16
±0.32
1.03
±0.15
2.93±1.33 1.58±0.66 1.71±0.75 1.60±0.62 0.67
±0.45
1.43±0.95
Delta 0.05
±0.13
0.04
±0.06
0.04
±0.05
0.01
±0.04
0.14±0.29 0.09±0.09 0.11±0.12 0.06±0.11 0.05
±0.10
0.10±0.22
p (follow-up vs.
Baseline)
6.34E-02 1.98E-
03
4.47E-
04
8.39E-
02
3.33E-02 2.02E-04 1.68E-04 1.19E-02 2.91E-
02
3.84E-02
Rate 0.02
±0.09
0.02
±0.03
0.02
±0.03
0.00
±0.02
0.05±0.17 0.04±0.05 0.05±0.06 0.03±0.05 0.02
±0.05
0.04±0.11
Effect Size 0.23 0.62 0.71 0.25 0.33 0.85 0.82 0.49 0.33 0.34
sample size (25%
reduction in Rate)
2286 333 251 2038 1171 177 188 519 1177 1097
sample size (50%
reduction in Rate)
573 85 65 511 295 46 49 132 296 276
MC_CER = mean cortical region SUVR using cerebellar cortex as reference; MC_BS = mean cortical region SUVR using brainstem as reference;
MC_CW = mean cortical region SUVR using core white matter as reference; MC_TW = mean cortical region SUVR using total white matter as reference;
MCRSF_CER = mean cortical region SUVR using cerebellar cortex as reference with RSF partial volume correction; MCRSF_BS = mean cortical region
SUVR using brainstem as reference with RSF partial volume correction; MCRSF_CW = mean cortical region SUVR using core white matter as reference
with RSF partial volume correction; MCRSF_TW = mean cortical region SUVR using total white matter as reference with RSF partial volume correction;
MCBP = mean cortical binding potential; MCBPRSF = mean cortical binding potential with RSF partial volume correction; delta = change in SUVR from
baseline to follow-up; p is the strength of the difference between follow-up and baseline SUVRs based on a paired t-test; Rate = the annual rate of SUVR
change; sample size is the estimated number of participants per arm needed to detect a 25% or a 50% reduction in amyloid accumulation rate due to
treatment with 80% power and a two-tailed type-I error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial.
doi:10.1371/journal.pone.0152082.t006
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In fact, PVC consistently increased the observed longitudinal percent change in measured PiB
uptake regardless of the reference region. Two separate characteristics of PVC technique may
be the causes of the beneficial effects. Firstly, PVC amplifies the signal we want to detect more
than the amplification of noise therefore improve signal to noise ratio. Secondly, without
PVC, MCSUVR and its change over time is dependent upon both amyloid deposition and
brain atrophy; when PVC is performed we can separate the two processes. Therefore, we
strongly recommend PVC especially in longitudinal studies aimed at detecting changes in
amyloid burden.
Full Dynamic Acquisition and Modeling
Moderate improvement was observed when full dynamic PET acquisition was available. As
previously reported [36], SUVR analysis is more sensitive to the choice of time window used
for quantification. Improved statistical power with full dynamic scanning likely is attributable
to greater consistency in the selection of the time window used for quantification. In short
acquisitions, uptake time may vary from one scan to the next. Regional binding potential esti-
mation provided improved statistical power in comparison to SUVR, as previously reported
[36]. Nevertheless, full kinetic modeling requires longer scan time and the quantification
requires more PET imaging expertise, both of which could lead to increased cost. However,
such increases in cost may be offset by improved accuracy, increased statistical power and
reduced sample size. This trade-off should be carefully evaluated at study design.
Observed Longitudinal Change
In this study, moderate annual rate of change in amyloid burden was observed with substantial
inter-individual variability. And it appears that the inter-individual variability was larger when
cerebellar cortex was used as reference than when white matter were used as reference. Partial
volume correction increased the magnitude of the annual rate of change no matter what refer-
ence region was used. Similar annual rate of change was observed in this cohort (0.02±0.05 in
MCBP) in comparison to our previous observations in a sporadic AD cohort (0.016±0.03 in
MCBP)[18]. Using ADNI [18F]-florbetapir data, Chen et al. [17] reported an annual rate of
SUVR change of 0.013±0.011 in the asymptomatic amyloid positive group, and an annual rate
of 0.012±0.014 in the MCI amyloid positive group using cerebral white matter as the reference.
A similar rate of change was also reported by Brendel et al. [16] using white matter as reference
region based on the same dataset. In comparison, in this current study in the DIAN cohort
using PiB as the tracer, we observed a substantially larger annual rate of 0.02±0.03 in SUVR in
a cohort that is a mixture of MCI (CDR = 0.5) and asymptomatic participants using similar ref-
erence region. The estimated sample size needed for anti-amyloid trials were similar between
the two studies. The difference in annual rate of change and similarity of estimated sample size
is likely a combined effects of cohorts, tracer, and quantification methods, and further investi-
gation is necessary.
Limitations
The analysis performed in this study is based on the DIAN cohort using PiB as the imaging
tracer. Whether our observations can be translated to other cohorts and/or using other amyloid
tracers remains to be determined. We focused our comparison of quantification methodology
on those utilizing structural MR obtained on the same participant. While MR data is generally
available for most of the ongoing neuroimaging studies, quantification methods that does not
require MR [37–39] have their advantages and warrant further investigation. In this study, we
focused on a single PVC technique in based on our previous experience [18]. This technique
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depends on segmentation of high resolution structural MR data. Other techniques that do not
rely on structural MR data are available, such as deconvolution based approaches [40] and res-
olution recovery techniques incorporated into image reconstruction [41], although they gener-
ally cannot achieve full recovery of the resolution. Nevertheless, these techniques is worth
investigating further as well because they can be applied in cases where only PET data are avail-
able. One approach we took to assess the stability and noise properties of reference region
tracer uptake was based on an IDAIF technique using population based parent compound
ratio for metabolites correction [30]. It should be pointed out that there is potentially group dif-
ference in tracer metabolism as well as inter individual variability which may introduce noise
into the estimated tracer uptake. This can be investigated by performing actual metabolites
measurement in a similar cohort. Nevertheless, the observation we obtained using this
approach is consistent with SUV analysis. Additional investigation is also warranted on the fea-
sibility of using an IDAIF approach for absolute quantification of amyloid burden in general.
Conclusion
We examined several technical variations in the approach to obtain quantitative and semi-
quantitative measurement of amyloid burden using PET imaging. PVC emerged as the strategy
that most consistently improved statistical power for the detection of both longitudinal changes
and across-group differences. This result accords with several previously reported studies
[16,18,21]. Among several reference regions, core white matter provided the greatest sensitivity
for the detection of longitudinal changes. However, the observed longitudinal change using
white matter reference may be confounded by processes unrelated to amyloid burden and
requires further investigation. We observed some advantages of acquiring full dynamic PET
rather than shorter scans. However, given the countervailing costs, it remains unclear whether
the advantages of full dynamic scanning outweigh the disadvantages. For the ADAD popula-
tion with PiB imaging, utilizing brainstem as a reference region with PVC may be optimal for
current interventional trials. Further investigation of technical issues in quantitative amyloid
imaging in different study populations using different amyloid imaging tracers is warranted.
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